Other languages Ceapro Inc.

Equities

CZO

CA1499071076

Market Closed - Toronto S.E. Other stock markets 12:46:26 07/05/2024 am IST			5-day change	1st Jan Change
0.245 ^CAD	0.00%		-5.77%	+28.95%

29/04	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/04	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	14/12
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	13/12
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	13/12
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	28/11
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	27/11
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	07/11
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	25/23/25
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	25/23/25
Ceapro Inc. Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	18/23/18
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director	07/23/07
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases	23/23/23
Ceapro on Findings That Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing, Tissue Regeneration	03/23/03
Ceapro Inc. Announces Positive Results from Research Collaboration with the Angiogenesis Foundation Conducted with Researchers At the University of Arizona	03/23/03
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations, Effective May 1, 2023	27/23/27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ceapro Inc.

Equities

CZO

CA1499071076

Other languages

Filters